A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects
Status:
Completed
Trial end date:
2010-10-18
Target enrollment:
Participant gender:
Summary
When humans eat, the bowels naturally secrete chemicals into the bloodstream which make
people feel full and which stop eating. One of these chemicals is known as "Pancreatic
Polypeptide" (PP). We have previously shown that injections of human PP reduces appetite and
food intake. We have now developed a very similar chemical, PP 1420, as a treatment for
obesity. PP 1420 has been tested in animals and has been shown to be safe, and to reduce
their appetite. This study will test PP 1420 for its safety and tolerability in humans.
Phase:
Phase 1
Details
Lead Sponsor:
Imperial College London
Collaborators:
Imperial College Healthcare NHS Trust Wellcome Trust